VAG 624Alternative Names: VAG624
Latest Information Update: 08 May 2006
At a glance
- Originator Novartis
- Class Antiacnes
- Mechanism of Action Sulfatase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Acne
Most Recent Events
- 19 Nov 2003 Phase-I clinical trials in Acne in USA (unspecified route)